Drug resistance of leukemic blasts is correlated to event-free survival and might be predicted by mRNA expression of drug resistance-related proteins. Methotrexate (MTX) is an important component in the treatment of childhood leukemia. Mechanisms of MTX resistance include (1) decreased transport via the reduced folate carrier (RFC), (2) altered levels of target enzymes, eg dihydrofolate reductase (DHFR) and thymidylate synthase (TS), (3) decreased ratio of folylpolyglutamate synthetase (FPGS)/folylpolyglutamate hydrolase (FPGH). We designed competitive templates for each of these genes to measure mRNA expression by quantitative RT-PCR and normalized the expression to that of ␤-actin. T-lineage acute lymphoblastic leukemia (T-ALL), relatively MTX resistant compared to common/preB-ALL, displayed higher mRNA levels of DHFR and TS (three-and four-fold higher, respectively; P Ͻ 0.001), while FPGS expression was lower (three-fold, P ‫؍‬ 0.006) compared to common/preB-ALL. The ratio of (DHFR ؋ FPGH)/(RFC ؋ FPGS) was more discriminating between T-ALL and c/preB-ALL (eight-fold higher; P Ͻ 0.001) than either target independently. Acute myeloid leukemia (AML) cells, considered MTX resistant, expressed two-fold lower levels of FPGS mRNA compared to c/preB-ALL (P ‫؍‬ 0.04). The ratio of FPGH/FPGS was more discriminating between AML and c/preB-ALL (fourfold higher; P ‫؍‬ 0.001) than either target independently. For the total group of 79 leukemic samples, mRNA expression of DHFR varied 549-fold and paralleled TS mRNA expression (r ‫؍‬ 0.80; P Ͻ 0.001). Although variations in mRNA expression resembled variations in functional activity, no direct correlations were found for RFC (58-fold variation in mRNA expression), FPGS (95-fold) and FPGH (178-fold). In conclusion, differences in mRNA expression of MTX resistance parameters between leukemic subtypes as detected by competitive RT-PCR are in line with known differences in MTX resistance. Leukemia (2000) 14, 2166-2175.
Introduction
For the treatment of many cancer types, patients are stratified based on clinical and laboratory features, such as age and histological phenotypic features of the tumor, eg maturation stage. For colorectal and gastric tumors, enzyme levels and mRNA expression of, eg thymidylate synthase (TS) were reported to be of prognostic value 1 and could therefore be applied for risk stratification of the patients. In this article, we report on a rapid standardized competitive template-based RT-PCR method requiring low numbers of cells to determine mRNA expression levels of proteins involved in causing methotrexate (MTX) resistance in childhood leukemia.
The classical risk criteria for childhood leukemia are immunophenotype, age, white blood cell count and cytogenetics. 2 More recently, in vitro cellular drug resistance was also reported to be a strong prognostic factor. 3 The major drugs in this respect are prednisone, L-asparaginase and vincristine, which are the backbone of induction chemotherapy. Induction therapy results in a complete remission in over 95% of children.
2 However, during/after subsequent maintenance therapy, 30% of the patients will experience a relapse. Methotrexate (MTX) is one of the keystones in most maintenance regimens. 4 Unfortunately, the importance of MTX resistance in causing a relapse is largely unknown as in vitro MTX resistance testing of clinical specimens by conventional cytotoxicity assays is not feasible. 5 Recently, an in situ thymidylate synthase inhibition assay 6 was adapted which could detect MTX resistance in relatively chemoresistant childhood leukemia subtypes. 5, 7, 8 The efficacy of MTX is determined by at least three parameters: (1) efficiency of cell membrane transport via the reduced folate carrier (RFC), 9, 10 (2) activity of the main target enzyme dihydrofolate reductase (DHFR) 11 and (3) efficiency of polyglutamylation. 12, 13 In fact, accumulation of MTX and MTX polyglutamates has been correlated with short-term antileukemic effect in vivo 14 and event-free survival. 15 Polyglutamylation of MTX is important for the intracellular retention of the drug and this process will increase the affinity for additional folate-requiring enzymes like TS. 16 Polyglutamylation is the result of the action of two enzymes: folylpolyglutamate synthetase (FPGS) and folylpolyglutamate hydrolase (FPGH). We and others described that the ratio of the activities of these enzymes is related to the in situ polyglutamylation efficiency for childhood leukemic blast samples. 12, 17 Intrinsic or acquired alterations in MTX membrane transport, DHFR levels and MTX polyglutamylation have been implicated with clinical resistance to MTX. 18 Identification of these parameters may therefore be of potential clinical interest to predict clinical resistance to MTX and for the possible design of alternative treatment strategies. However, a significant number of cells is required to accurately establish the activities of RFC, DHFR, TS, FPGS and FPGH. For most clinical samples obtained from children, large numbers of cells are generally not available for research purposes. Therefore, we designed competitive templates (CTs), based on a previously described method, 19 for RFC1, DHFR, TS, FPGS and FPGH to determine the mRNA expression of these MTX-resistance related proteins by RT-PCR requiring low numbers of cells.
Expression of all targets was measured using a mastermix containing cDNA and the standardized pre-mixed CTs. 20 Preparing one mastermix for all target genes containing cDNA and the premixed CTs ensures that the cDNA/CT ratio is the same in each reaction tube, while using the same CT mixture (or a dilution of it) in subsequent experiments ensures that the relative amount of each CT is constant. Therefore, data from one experiment are directly comparable to data from another. The assay is a strong method which can easily be adapted by other laboratories to address a broad range of research questions. [21] [22] [23] In this study, we report on underlying mechanisms of MTX resistance at the level of mRNA in childhood leukemia subtypes.
Materials and methods

Reagents
RNAzol was purchased from Campro Scientific (Veenendaal, The Netherlands); Moloney murine leukemia virus reverse transcriptase (M-MLV-RT) and RNase inhibitor (25 IU/l) were obtained from Promega (Madison, WI, USA). Deoxyribonucleotides (dNTPs), random hexamers, and Taq polymerase (5 IU/l) were purchased from Pharmacia Biotech (Roosendaal, The Netherlands). RESponse Research agarose was obtained from Biozym (Landgraaf, The Netherlands).
Patient samples and cell lines
Mononuclear cells were derived after informed consent from 38 children with common or precursor-B acute lymphoblastic leukemia (c/preB-ALL), 21 with T-lineage ALL (T-ALL) and 20 with acute myeloid leukemia (AML) and isolated by density gradient centrifugation within 24 h after sampling as described previously. 24 Contaminating non-leukemic cells were removed by immunomagnetic beads 25 to a percentage of leukemic cells above 80% as morphologically determined by May-Grü nwald-Giemsa staining of the cytospins. Cells were washed twice in RPMI (Gibco BRL, Breda, The Netherlands) containing 2% fetal calf serum and used for functional activity assays. Data on polyglutamylation and its enzymes have been reported in detail previously for a significant number of samples. 12 For RNA isolation, the washed cells (5 × 10 6 ) were lysed in 1 ml RNAzol, snap-frozen in liquid nitrogen and stored at −80°C. Seven CCRF-CEM sublines with different transport characteristics were grown in RPMI-medium in 5% CO 2 and harvested at logarithmic phase.
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RNA extraction and reverse transcriptase reaction
RNA isolation was according to manufacturer's directions except for a repetition of the chloroform-phenol extraction, and an extension of the precipitation step in isopropanol at −20°C for at least overnight. A PCR reaction was performed on each RNA sample using ␤-actin primers situated in exons 3 and 4 (Table 1) to determine possible genomic DNA contamination. DNA contaminated samples were excluded from this study. Filter tips (Costar, Badhoevedorp, The Netherlands) were used throughout this study to avoid cross-contamination.
Total RNA of 5 × 10 6 cells was reverse transcribed by M-MLV-RT (final concentration: 20 IU/l), including RNase inhibitor (0.6 IU/l), bovine serum albumin (0.2 g/l), dNTPs (1 mM) and random hexamers (45 ng/l) in 50 l at 42°C for 2 h. After incubation, the mixture was heated to 95°C to denature M-MLV-RT and stored at −20°C.
Preparation of competitive template standard mixtures
Primers to synthesize competitive templates (CTs) (F and R 1 R 2 ) and to amplify the target gene (native template, NT) (F and R 1 ) were selected by Oligo software as previously described. 20, 30 Design of the primers was based on an optimal annealing temperature of 58°C, absence of hairpins and no predictable stable primer-dimer formations. Resulting primers for target genes and for the two reference genes are presented in Table 1 .
CTs were synthesized by amplification from a cDNA sample known to express the relevant gene, using the same forward primer (F) as used for amplification of the NT ( Figure  1a ). Since CTs and native cDNA should be amplified by the same primer set (F and R 1 ), the reverse primer R 1 was annealed to a new primer R 2 . The combination of F and R 2 was designed to result in a PCR product of about 75% of the length of the PCR product of the F and R 1 primers. This hybrid R 1 R 2 primer and the forward primer F were used to synthesize CTs by amplification of cDNA known to express the target gene (Figure 1b) . PCR products of a specific CT were pooled, size separated on an agarose gel, gel purified and quantified by co-electrophoresis with a size marker, as previously described. 21 Co-amplification using primer F and R 1 of a cDNA sample with known amounts of competitive template will result in two PCR products of different lengths, which can be separated and quantified by gel electrophoresis (Figure 1c) . A representative gel is shown in Figure 2 .
CTs were mixed in combinations which were based on preliminary experiments using a representative cell line and 10 patient samples. For this study, three different stocks were prepared in which the CTs for ␤-actin, GAPDH and the other targets were premixed in different ratios: (1) 10 /10 −16 M representing the concentrations of ␤-actin/GAPDH/other targets in the mixtures, respectively. These mixtures could subsequently be diluted further depending on the sample without disturbing the initial relationships of the CTs present. Mixtures have now been stored for many targets for years and in none of the investigated templates was detectable degradation noted.
Polymerase chain reaction
Co-amplification of cDNA samples with CTs ensured accurate quantification of the expression of NT. In order to normalize The 5Ј and 3Ј positions of the forward (F) and reverse (R) primer, respectively, are provided. For the RT-negative PCR reaction, ␤-actin primers were used for which the position within the genomic DNA is provided. CT-primer is similar to R 1 R 2 in Figure 1 .
Figure 1
Design of competitive templates (CTs). (a) A forward primer (F) and reverse primer (R 1 ) were designed according to conventional PCR requirements. A second reverse primer (R 2 ) was designed to result in the generation of a PCR product of about 75% of the length of the FR 1 -amplified product. Primer R 1 was ligated to R 2 to result in a reverse primer R 2 R 1 ; (b) amplification with F and R 2 R 1 will result in a 'competitive template (CT)' flanked by the F and R 1 sequence; (c) co-amplification of known amounts of CT with unknown amounts of native target (NT) results in two products which differ in length and can be separated on agarose gels. Calculation of the amount of NT in the cDNA sample, together with the requirements for the design of primer R 2 , is provided in the Materials and methods section.
the expression of a target gene to the expression of a reference gene, one single master mix was prepared for every cDNA sample containing PCR buffer (1×), MgCl 2 (2.5 mM), dNTPs (200 M), sample cDNA (0.2 l per reaction tube) and the appropriate CT mix (1 l per reaction tube) in a volume of 41 l. Primers (4l, final concentration: 4 ng/l of each primer) were added to aliquots of this master mixture to amplify the targets in different tubes. Reaction mixtures were overlayed with mineral oil (Sigma, St Louis, MO, USA) and cycled in a MJ Research PTC-200 (Biozym) with 1 min steps of denaturation at 94°C, primer annealing at 58°C and elongation at 72°C for 35 cycles. The first cycle included a 7 min denaturation step, whereas in the last cycle, the elongation period was extended to 7 min. Taq polymerase (5 l, final concentration: 0.02 U/l) was added to the reaction mixture in the first cycle after 2 min incubation at 94°C (hot start). PCR products were separated by 100 V electrophoresis for 3 h on 2% agarose gels containing 0.1 mg/ml ethidium bromide. Quantification was by digital image analysis using Molecular Analist (Biorad, Veenendaal, The Netherlands). Concentrations of native template (NT) molecules in the cDNA samples can be calculated by the ratio of NT/CT after ampli-
Figure 2
Representative agarose gel of seven genes, the two house keeping genes, and the five target genes for DHFR, RFC1, TS, FPGS and FPGH. The gel was run under conditions described in Materials and methods. The top of the figures gives the concentrations of the CTs used in the PCR reaction. At the left of the figure the size of base pairs is given. For each gene the top band represents the native template, and the lower band the CT. The band in the middle is the heterodimer.
fication and the molarity of the CT mixture used as described previously. [20] [21] [22] [23] Since ethidium bromide staining is proportional to the number of base pairs present, pixel intensity (PI) needs to be corrected for fragment size to obtain a measure for number of molecules present. In addition, heterodimers (HD) consist of a NT and a CT molecule and should therefore also be taken into account. The identity of the bands for various targets was confirmed by sequencing [20] [21] [22] [23] which also revealed that the heterodimers of NT and CT molecules were represented by the additional band (Figure 2 ). This band was scanned separately. In the calculation of the NT, CT and heterodimers band the length of the transcripts was taken into account to calculate the gene expression. Results were evaluable when the ratio (amount of NT)/(amount of CT) was between 0.1 and 10. The concentration of the reference genes ␤-actin and GAPDH is also calculated, so that mRNA expression can be normalized to compare the patients' samples. Normalization to the expression of a reference gene was only valid when results for both target gene and for reference gene were obtained using the same mastermix.
Quantification of mRNA expression was calculated as follows:
concentration NT = (amount NT/amount CT) × molarity CT mixture × (l CT/l cDNA); amount of NT = (PI NT band +0.5 × PI HD)/length NT; amount of CT = (PI CT band +0.5 × PI HD)/length CT, where CT is competitive template, HD is heterodimer, NT is native template, PI is pixel intensity.
Functional assays MTX membrane transport via the reduced folate carrier (RFC):
5 × 10 6 childhood leukemia cells were incubated in anion-free buffer (20 mM HEPES and 225 mM sucrose, set to pH 7.4 with MgO, as described previously) 27 at 37°C in the presence of 3 H-MTX (2 M, final specific activity: 2 Ci/mmol). Incubation was for 15 min to optimally differentiate between Leukemia patient samples within the linear phase. The uptake was stopped by adding 10 ml ice-cold PBS and cells were washed three times. The final cell pellet was resuspended in 350 l PBS; an aliquot was counted for cell number and the remainder for radioactivity. A control sample was included in which an excess of 1 mM MTX (final specific activity: 4 Ci/mmol) was added to correct for non-MTX specific uptake.
FPGS assay:
15 × 10 6 cells were washed twice with PBS, pelleted and snap frozen. Cellular protein (200 g), obtained via sonification, was incubated for 2 h with MTX (250 M) and 3 H-glutamic acid (Moravek, final concentration 4 mM, final specific activity: 6.6 Ci/mmol) as described previously. 12 
FPGH assay:
4 × 10 6 cells were washed twice with PBS, pelleted and snap frozen. Cellular protein (25 g), obtained via sonification, was incubated for 1 h with MTX-Glu 2 (Schirks Jona, Switzerland, final concentration: 100 M) as described previously.
12 MTX-Glu 2 was used as a substrate to avoid the complex cleavage pattern with hydrolysed products subsequently serving as substrates again.
In situ polyglutamylation assay:
10 × 10 6 cells were incubated in 5 ml culture medium for 24 h with 
Statistics
To analyze differences between the different subtypes of childhood leukemia, the Mann-Whitney U test was applied. A correlation between mRNA expression levels and functional activities or between mRNA expression of two targets was analyzed by the Spearman correlation test.
Results
Validation of competitive template-based RT-PCR
Co-amplification of the competitive template (CT) and the native template (NT) should show linearity for the ratio of CT/NT initially present as compared to that ratio after PCR amplification. The slopes obtained by plotting the calculated ratio of CT/NT initially added to the amplification reaction mixture against the ratio obtained after amplification were approximately 1 for RFC1, FPGS and FPGH and 2 for DHFR and TS. Mean curve fit coefficients (r 2 ) values were 1.0 for RFC1; 0.97 for DHFR; 0.98 for TS; 0.99 for FPGS and 1.0 for FPGH (Figure 3 ). Given the excellent linearity the ratio between the target and reference gene will remain constant during the cycles, even when amplified to the plateau phase. However, the number of cycles was kept limited to prevent that amplification would reach the plateau phase.
In order to determine reproducibility, three samples of 5 × 10 6 freshly isolated cells were frozen in RNAzol for RNA extraction for two patients. For one of these patients, three additional samples of 5 × 10 6 cryopreserved cells were also resuspended in RNAzol and frozen. All RNA isolations and reverse transcription reactions were performed on different occasions. mRNA expression of the different targets was within 50% variability, except for one target for which the results were 1.12, 0.37, 0.37, 0.24, 0.37, 0.32 (70% variability). Since one value was a clear outlier (outside range of 2 × s.d. and according to the Q-test) we considered it valid to exclude this datapoint. Exclusion of 1.12 resulted in 17% variability. When during routine analysis of samples a similar variation was observed, we repeated the analysis until we could determine which value would qualify as an outlier. It was reported earlier 21, 31, 32 that with this degree of reproducibility it is possible to confidently measure two-fold differences in gene expression.
Seven variant lines of human CCRF-CEM cells with impaired and upregulated MTX membrane transport capacities were screened for RFC1 mRNA normalized to ␤-actin expression, and were found to differ 47-fold. A good correlation between mRNA expression and RFC-mediated influx of MTX was observed (r = 0.82; P = 0.02).
Reference genes mRNA expression of GAPDH relative to ␤-actin mRNA expression varied 55-fold in patients' samples, with no difference in median levels between c/preB-ALL and AML; T-ALL samples tended to contain two-fold more GAPDH relative to ␤-actin (P = 0.09). GAPDH mRNA concentration was strongly correlated to ␤-actin mRNA concentration in the group of 70 untreated leukemia cDNA samples (r = 0.76, P Ͻ 0.001). The variation in the ratio between ␤-actin/GAPDH was caused by some outliers in each group; exclusion of these outliers reduced the variation between the groups; the range varied less than 16-fold in the c/preB-ALL, and 10-fold in the T-ALL and AML groups with an overal variation of 19-fold for all groups together. The means for the ratios ␤-actin/GAPDH varied from 135 to 149 (183-257 for all samples including outliers). Medians for the ratios varied between 84 and 117 (85-128 for all samples including outliers). Analyzing the data obtained for the targets by normalization to GAPDH compared to data normalized to ␤-actin expression resulted in similar differences. The differences in ␤-actin/GAPDH expression in the various outliers may be related to the different functions of these house keeping genes; ␤-actin is a component of the cytoskeleton which varies with cell size, 20 while GAPDH is a metabolic enzyme which is more likely to vary depending on the degree of malignancy. 33 From this point of view it seems preferable to use ␤-actin as the preferred gene to normalize. Data hereafter are expressed as normalized to ␤-actin expression.
RFC1
Within a group of 72 childhood leukemia samples, RFC1 mRNA expression varied 58-fold, which was similar to the variation of the functional transport activities (67-fold). However, there was no correlation of RFC1 mRNA expression and functional activity, which could be determined for 22 samples (data not shown). No significant difference in RFC mRNA expression was found between the separate subgroups of 34 c/preB-ALL, 20 T-ALL and 18 AML samples (Figure 4a ).
Target enzymes
mRNA expression of DHFR and TS varied over 500-and 100-fold, respectively, with a median 3.5-and 3.8-fold higher DHFR and TS mRNA expression, respectively, for 18 T-ALL compared to 36 c/preB-ALL samples (P Ͻ 0.001) (Figure 4b and c). No difference in median values was observed between c/preB-ALL and AML samples. We did not determine DHFR activity due to the number of cells required; 34 functional TS activity was also not determined for these samples. A strong correlation between mRNA expression of DHFR and mRNA expression of TS was found within the total group of 70 samples (r = 0.80, P Ͻ 0.001); similar correlations were observed within the separate subgroups ( Figure 5 ).
Polyglutamylation enzymes
Variation in mRNA expression of FPGS and FPGH among all samples was 95-and 178-fold, respectively. Previously, we had also shown a high variation in functional activity (125-and Ͼ1000-fold, respectively). 12 Median FPGS mRNA expression was 2.7-fold lower in 20 T-ALL samples and 1.6-fold lower in 19 AML samples compared to 31 c/preB-ALL (P = 0.006 and P = 0.04, respectively) (Figure 4d ). No significant difference was detected in FPGH mRNA expression between c/preB-ALL and T-ALL or AML (Figure 4e) . No correlation between mRNA expression and functional activity was observed for FPGH (n = 36) or for FPGS (n = 21).
MTX resistance ratios
The ratio of FPGH/FPGS mRNA expression might be related to in situ polyglutamylation efficiency as previously reported for the ratio of FPGH/FPGS functional activities. 12 For a smaller group of leukemic samples, of which both mRNA expression levels and polyglutamylation efficiencies were determined (13 c/preB-ALL, 11 T-ALL and 12 AML samples), the ratio of FPGH/FPGS mRNA expression correlated with the percentage of the pharmacologically important MTX-Glu 4-6 (r = −0.40, P = 0.017) ( Figure 6 ) for these 36 samples. However, within this group the correlation was stronger for FPGS independently (r = 0.46, P = 0.005).
The median FPGH/FPGS mRNA ratio was higher in 16 T- Correlation between DHFR and TS mRNA expression. Data from all patients were plotted. The correlation coefficient was 0.80 (P Ͻ 0.0001).
ALL (three-fold, P = 0.004) and in 15 AML samples (four-fold, P = 0.001) compared to 31 c/preB-ALL samples for which both FPGS and FPGH mRNA levels were evaluable (Figure 7a) . Analysis of this group of samples for which both FPGS and FPGH mRNA expression data were available, revealed that the difference between c/preB-ALL and AML was more pronounced for the ratio FPGH/FPGS (four-fold, P = 0.001) than for FPGS mRNA expression (two-fold, P = 0.009); this was not observed for the difference between c/preB-ALL and T-ALL.
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Figure 6
Correlation of the ratio FPGH/FPGS mRNA expression levels and percentage of MTX present as the long-chain polyglutamates, MTX-Glu 4-6 . Polyglutamylation was determined after 24 h exposure to 1 M Interestingly, the ratio FPGH/FPGS mRNA expression tended to be correlated to the ratio calculated for the functional activity in a group of 11 samples for which these four parameters were determined (r = 0.59, P = 0.056).
Since a high expression of DHFR and/or FPGH or a low expression of FPGS and/or RFC are thought to result in relative MTX resistance, we calculated ratios of (DHFR × FPGH)/(RFC × FPGS). The median value of this ratio was 1.3 in c/preB-ALL samples. The median ratio was higher for T- ALL (eight-fold, P Ͻ 0.001), and for AML (four-fold, P = 0.04) (Figure 7b) .
Discussion
The present report shows that mRNA levels encoding for DHFR and TS are higher in T-ALL compared to c/preB-ALL, whereas the expression of FPGS mRNA was lower in T-ALL and AML. For FPGH and RFC1, no differences were observed in mRNA expression between the leukemia subtypes.
Evaluation of mRNA expression levels is becoming increasingly important in biomedical research. The introduction of RT-PCR provided a tool to establish mRNA expression levels in low numbers of cells. This is an advantage over the conventional Northern blotting experiments, which require relatively large amounts of RNA and cannot be used for proteins with a low mRNA expression. Also, for functional transport and enzyme assays large quantities of material are required, which are often not available from patients. Without proper controls the RT-PCR is difficult to apply as a quantitative instrument. One approach to determine mRNA molecules within a cDNA sample, is the 'serial dilution PCR': 9,35,36 the slope obtained by plotting the amount of PCR products as measured by densitometry or radioactivity against the dilution range of cDNA is representative of the amount of target molecules present in that cDNA sample. This 'dilution-approach' requires amplification to be within the linear phase and is relatively laborintensive. Also, in Real-Time PCR, in which the appearance of a fluorescent signal is taken as a cut-off point, linearity of the dilutions is an important feature for the reproducibility of the assay. In the present study, we applied a previously reported method, 20 in which standardized mixtures of competitive templates (CTs) were used to measure mRNA expression levels of target genes and reference genes simultaneously. Because the relative ratios of the CTs are preserved in all experiments, relative gene expression can be reliably compared both intra-and interexperimentally. The inclusion of CTs in PCR reaction mixtures also allows quantitation of PCR products that were amplified to the plateau phase. 37 The CT-RT-PcR method has been compared to Northern blots and Real-Time PCR analysis for several genes, such as various cytochrome p450 subtypes, and found to correlate very closely. 21, 31, 32 For the genes investigated in this study, expression in clinical samples was too low to perform Northern blots.
Using this approach, we investigated mRNA expression levels of proteins contributing to MTX resistance in c/preB-ALL, T-ALL, and AML samples. T-ALL cells are relatively more resistant to MTX in vitro compared to c/preB-ALL. 5 Determination of MTX resistance parameters in T-ALL revealed that: (1) RFC-mediated transport is not impaired, 38 (2) DHFR is frequently expressed at high levels in subclones of individual patients' samples 39 and (3) polyglutamylation is defective due to a low FPGS activity, 12, 40 but this impaired polyglutamylation is not associated with a high FPGH activity. 12 In accordance with these observations on the protein level, we observed a higher mRNA expression of DHFR, a lower mRNA expression of FPGS and no difference in RFC (confirming previous reports) [38] [39] [40] [41] or FPGH mRNA expression in T-ALL compared to c/preB-ALL.
AML patients are thought to be intrinsically MTX resistant and MTX is generally not included in their treatment. 42 The intrinsic MTX resistance has been described at the level of (1) MTX membrane transport 9 (although this was not observed in our laboratory using 3 H-MTX transmembrane uptake assay), 43 (2) the target enzyme DHFR 34 and (3) polyglutamylation associated with a low FPGS activity 12, 40 and a high FPGH activity. 12 mRNA expression levels as measured in the present study are consistent with the low FPGS activity, but no differences were observed between AML and c/preB-ALL for RFC, DHFR, TS and FPGH. FPGH mRNA expression, however, might be of relevance as suggested by the more pronounced difference between AML and c/preB-ALL based on the ratio of FPGH/FPGS mRNA levels than based on mRNA expression of FPGS alone.
The observation that DHFR expression is strongly correlated to the mRNA expression coding for TS, is consistent with the fact that both proteins are regulated by the same transcription factor, E2F. 44, 45 The high expression of these two enzymes in T-ALL samples might reflect the fact that T-ALL is often associated with a high white blood cell count. The role of TS in conferring MTX resistance remains controversial. Whereas low TS activity has been reported to result in MTX resistance in cell lines, 46 ,47 a high activity of TS can also result in MTX resistance. 48 Studies on clinically derived colon tumors dem-onstrate that TS mRNA levels reflect TS protein level as measured by immunohistochemistry and enzyme activity assays. 1, 35 Immunohistochemical staining has been associated with outcome of adjuvant treatment, 49 while both enzyme activity assays 50 and mRNA expression levels 51 predict the response to 5-fluorouracil treatment.
The relationship between RFC1 mRNA expression and MTX membrane transport in leukemia cells was suggested by an earlier study in which six of the nine transport-deficient samples had a low RFC1 mRNA expression. 9 Indeed, we observed a correlation between RFC1 mRNA expression and MTX membrane transport in a panel of cell lines. In contrast, we did not find such a correlation between RFC gene expression and functional activity. However, cell lines are grown in very controlled conditions whereas patient samples are likely to demonstrate a large heterogeneity in aspects determining functional MTX membrane transport. The lack of correlation between mRNA expression and functional activity might be provoked by differences in the regulation of RFC transport, eg by alterations in intercellular folate status 52 or the presence of mutations in the RFC1 gene. 29, [53] [54] [55] Unfortunately, RNA-based methods are inherently unable to detect mutations in the target genes, except when present in the transcript, which would then be visible as an aberrant transcript on the gel. Only when the mutation affects the transcript level, which may happen for some of the RFC mutations, will this be detected with RNA-based methods. Similarly, functional activity assays do not detect mutations either, except when leading to increased or decreased enzyme levels or aberrant kinetics. Basically, a low mRNA expression most likely will potentially result in a low activity, which may subsequently be altered by known regulators such as folate status. 52 However, such a patient would be at potential risk when the folate homeostasis alters, which frequently happens during malignancy. This post-translational regulation may explain why we did not find indications for an overall low expression RFC1 mRNA in the relative MTX-resistant leukemia subtypes. Also, for functional RFC-mediated transport of 3 H-MTX, a wide interpatient variation was observed. This does, however, not exclude that RFC deficiency may be responsible for MTX resistance in individual patients. Also, Zhang et al 38 observed a poor correlation between functional activity and RFC expression. Only exclusion of two c/preB-ALL resulted in a correlation in a group of eight c/preB-ALL patients but not in T-ALL. Apparently in clinical samples there is a poor correlation between functional activity and gene expression, which does, however, not exclude that lack of gene expression confers resistance.
Similarly the range of mRNA expression equals the range in enzymatic activity of FPGS, 12 but FPGS mRNA and functional activity were correlated. Only Galpin et al 56 observed such a relationship in 11 samples obtained from six patients before and after MTX treatment, which may be due to potential upregulation by MTX of FPGS within leukemic blasts. 40 Also in subtypes of cell lines with induced resistance, a relation was found, 35, 57, 58 but not in a panel of human CEM leukemia cell lines. 59, 60 Post-translational modifications may explain this discrepancy since mRNA levels correlated with protein expression, but not with activity of FPGS. 61 Also, mutations in the FPGS gene may lead to this discrepancy, but the occurrence in the FPGS gene is less intensively explored than for the RFC gene. The data in cell lines, however, indicate that a low gene expression (intrinsic or caused by drug treatment) leads to a marked decrease of lack of FPGS activity; screening for FPGS gene expression would enable the detection of these Leukemia samples. This explains why the lower mRNA expression of FPGS in T-ALL and AML compared to c/preB-ALL, is in accordance with the reported lower functional activity of FPGS in these leukemia subtypes. 12, 40 Regarding FPGH, the enzyme activity is very much dependent on the intracellular environment, since the enzyme is only maximally active in lysosomes. Mutations have not yet been described, which might explain the lack of correlation between mRNA expression and activity levels. The three-fold higher FPGH activity in AML compared to c/preB-ALL samples 12 was not associated with higher FPGH mRNA.
Empirically, we have observed that when multiple genes add to a phenotype that positively acting genes should be multiplied and put in the numerator of the index and that genes which act negatively should be put in the denominator. For functional activities of FPGS and FPGH we had already observed that the ratio FPGS/FPGH correlated with MTX-polyglutamylation. Similarly, we now observe that the ratio for the genes of FPGS/FPGH was more discriminating within the same group of AML and c/preB-ALL samples than FPGS independently and was correlated with the percentage of MTX present as MTX-Glu 4-6 .
Since both polyglutamylation efficiency 15 and DHFR levels 39 have been shown to be prognostically important, analysis of these mRNA expression profiles might rapidly identify patients with a poor prognosis using a low number of cells. To provide insight into the overall MTX resistance profile at the level of mRNA expression and to exclude any possible interference of the reference gene, we analyzed differences between the immunophenotypes with differential MTX resistance profiles using a MTX resistance index (DHFR × FPGH/RFC × FPGS). Gene expression indices were previously used to better characterize the malignant phenotype in bronchial epithelial cells. 23 Since all T-ALL samples displayed a higher MTX resistance index than the median ratio observed for c/preB-ALL samples, this index discriminates very well between c/preB-ALL and T-ALL. The ratio of FPGH/FPGS mRNA expression is more predictive to discriminate between AML and c/preB-ALL. These results might suggest that an impaired polyglutamylation is the predominant factor in causing MTX resistance in AML, whereas for T-ALL differences also at the level of DHFR are of importance.
In conclusion, the CT-RT-PCR method is a rapid, low cell number requiring and reproducible assay to measure mRNA levels of MTX resistance-associated proteins in childhood leukemia. The ability to combine multiple gene expression values obtained by this method into indices is an additional advantage. This report shows that differences in MTX resistance between leukemia subtypes are detectable at the level of mRNA and suggests that the CT-RT-PCR adds to the identification of poor risk patients.
